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Background
EZH2 (enhancer of zeste homolog 2) is a member of the 
Polycomb-group (PcG) family and encodes a histone 
methyl  transferase that is the catalytic component of the 
polycomb repressive complex (PCR)2 [1]. Th  e PRC2 
complex has a role in establishing methylation marks on 
histone H3 (triMe-K27 H3) to initiate chromatin conden-
sation and silencing of genes involved in developmental 
processes [2,3]. PcG proteins are known to be essential in 
maintaining self-renewal and pluripotency of stem cells 
[4], and their deregulation has been linked to cancer [5].
Th   e cancer stem cell (CSC) hypothesis proposes that a 
limited subpopulation of cancer cells has self-renewal 
capacity and is responsible for tumor growth [6]. 
According to the CSC hypothesis, progression towards 
aggressive behavior can ultimately be traced to changes 
that occur in the CSCs, or tumor initiating cells (TICs). 
However, experimental data on the molecular changes 
and the mechanism by which they could occur have been 
lacking. In breast cancer, stem cell-like properties 
associate with expression of CD44, and negativity/low 
CD24, that is CD44+/CD24-/low [7]. Recently, Chang and 
colleagues [8] studied EZH2 in CD44+/CD24-/low cells, or 
breast tumor initiating cells (BTICs), and described an 
important link to genomic instability, activation of RAF1-
β-catenin signaling, and expansion of the BTIC population.
The article
Chang and colleagues [8] demonstrate that increased 
EZH2 in CD44+/CD24-/low cells correlates with their 
increased abundance, that is, the proportion of CD44+/
CD24-/low cells. Increased EZH2 in CD44+/CD24-/low cells 
was correlated with decreased RAD51 levels. Using 
chromatin immunoprecipitation (ChIP), the authors 
show that EZH2, and other PRC1/PRC2 proteins, are 
recruited to a putative Ploycomb response element on 
the RAD51 promoter. Here, hypoxia in the micro  environ-
ment was identiﬁ   ed as a potential cause of EZH2 
upregulation. Th  e  RAD51 gene has a well established role 
in DNA repair through homologous recombination and, 
accordingly, EZH2-mediated epigenetic repression of 
RAD51 associates with accumulation of DNA damage 
and chromosome abnormalities.
Using protein arrays, the authors identiﬁ  ed increased 
expression of the RAF1 gene as a potential change asso-
ciated with EZH2-induced genomic instability. Impor-
tantly, this association was found to be a consequence of 
acquired DNA copy number gains over the RAF1 gene at 
3p25.2, resulting in activation of ERK and β-catenin, 
shown to confer survival and proliferative advantages for 
CD44+/CD24-/low cells. Importantly, inhibition of RAF1-
MEK-ERK-β-catenin activation by small molecule 
inhibitors (AZD6244, Sorafenib) leads to eﬀ  ective elimi-
na  tion of CD44+/CD24-/low cells - that is, BTICs - suggest-
ing potential implications with respect to clinical 
manage  ment of the disease.
Viewpoint
Th   e most important insight from Chang and colleagues 
[8] is the observation that genomic instability induced by 
EZH2-mediated epigenetic repression of DNA repair, 
that is, RAD51, results in expansion of the BTIC popu-
lation. Further, the order in which these changes occur 
did not inﬂ  uence the eventual outcome - that is, over-
expression of EZH2 has the same eﬀ  ect as knock-down of 
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© 2011 BioMed Central LtdRAD51. In this context, RAF1 ampliﬁ   cation was des-
cribed as a recurrent oncogenic consequence of down-
regulated DNA repair leading to activation of ERK and 
β-catenin and the consequent promotion of the BTIC 
population. In breast cancer, EZH2 overexpression has 
previously been linked to aggressive and poorly diﬀ  er-
entiated carcinomas [9], and downregulated DNA repair 
[10]. Th  e insights provided by Chang and colleagues 
relate to the identiﬁ  cation of EZH2 in augmenting BTICs 
through epigenetic repression of DNA repair, leading to 
aggressive disease. Th  ese results are consistent with 
clonal evolution of CSCs, that is, the notion that aggres-
sive secondary CSCs can arise from the primary popula-
tion of CSCs. Th  e clinical relevance relates to potential 
beneﬁ  ts from RAF1/MEK/ERK inhibitors in the treat-
ment of breast cancer patients, and in preventing disease 
progression. Further, poly ADP ribose polymerase 
(PARP) inhibitors are highly eﬀ  ective in targeting cancer 
cells with homologous recombination defects and there-
fore hold unexplored potential in this regard, that is, in 
targeting secondary CSCs [11].
Although somatic mutations in DNA repair genes are 
rare in sporadic cancers, it is well established that suscep-
tibility to cancer is commonly linked to inherited 
mutations in DNA repair genes, for example, BRCA1, 
BRCA2, PALB2, WRN and MLH1 [12]. Th   is has led some 
to speculate that defects in DNA repair genes cannot 
explain instability in sporadic cancers [12], whereas 
others have emphasized epigenetic mechanisms [13]. 
Chang and colleagues [8] describe results suggesting a 
causa  tive link between epigenetic inactivation of DNA 
repair, the emergence of genomic instability, and cancer 
progres  sion. In breast cancer, epigenetic inactivation of 
the  BRCA1 gene occurs through CpG island hyper-
methylation [14,15]. BRCA1 is essential in DNA repair of 
double-strand breaks, with RAD51 as a crucial partner 
for error-free repair by homologous recombination [16]. 
Recently, Lim and colleagues [17] demonstrated that 
BRCA1 defective breast cancers represent an expanded 
population of luminal progenitor cells. Th   is is consistent 
with the results described in Chang and colleagues [8], 
demonstrating DNA repair defects and expansion of 
tumor cells with progenitor/stem-cell characteristics. In 
conclusion, an important task in future research will be 
to explore the relationship between epigenetic repression 
of DNA repair, the induction of genomic instability, and 
markers of CSCs.
Abbreviations
BTIC, breast tumor initiating cell; CSC, cancer stem cell; PcG, Polycomb-group; 
PCR, polycomb repressive complex.
Competing interests
The authors declare that they have no competing interests.
Author details
1Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical 
Research Institute, 08908 L’Hospitalet, Barcelona, Catalonia, Spain. 2Institucio 
Catalana de Recerca i Estudis Avançats, 08010 Barcelona, Catalonia, Spain.
Published: 25 May 2011
References
1.  Simon JA, Lange CA: Roles of the EZH2 histone methyltransferase in cancer 
epigenetics. Mutat Res 2008, 647:21-29.
2.  Pasini D, Bracken AP, Hansen JB, Capillo M, Helin K: The polycomb group 
protein Suz12 is required for embryonic stem cell diff  erentiation. Mol Cell 
Biol 2007, 27:3769-3779.
3.  Lee TI, Jenner RG, Boyer LA, Guenther MG, Levine SS, Kumar RM, Chevalier B, 
Johnstone SE, Cole MF, Isono K, Koseki H, Fuchikami T, Abe K, Murray HL, 
Zucker JP, Yuan B, Bell GW, Herbolsheimer E, Hannett NM, Sun K, Odom DT, 
Otte AP, Volkert TL, Bartel DP, Melton DA, Giff  ord DK, Jaenisch R, Young RA: 
Control of developmental regulators by Polycomb in human embryonic 
stem cells. Cell 2006, 125:301-313.
4.  Rajasekhar VK, Begemann M: Concise review: roles of polycomb group 
proteins in development and disease: a stem cell perspective. Stem Cells 
2007, 25:2498-2510.
5.  Huang TH, Esteller M: Chromatin remodeling in mammary gland 
diff  erentiation and breast tumorigenesis. Cold Spring Harb Perspect Biol 
2010, 2:a004515.
6. Clevers  H:  The cancer stem cell: premises, promises and challenges. Nat 
Med 2010, 17:313-319.
7.  Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF: 
Prospective identifi  cation of tumorigenic breast cancer cells. Proc Natl 
Acad Sci U S A 2003, 100:3983-3988.
8.  Chang CJ, Yang JY, Xia W, Chen CT, Xie X, Chao CH, Woodward WA, Hsu JM, 
Hortobagyi GN, Hung MC: EZH2 promotes expansion of breast tumor 
initiating cells through activation of RAF1-beta-catenin signaling. Cancer 
Cell, 19:86-100.
9.  Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, 
Otte AP, Hayes DF, Sabel MS, Livant D, Weiss SJ, Rubin MA, Chinnaiyan AM: 
EZH2 is a marker of aggressive breast cancer and promotes neoplastic 
transformation of breast epithelial cells. Proc Natl Acad Sci U S A 2003, 
100:11606-11611.
10.  Zeidler M, Varambally S, Cao Q, Chinnaiyan AM, Ferguson DO, Merajver SD, 
Kleer CG: The Polycomb group protein EZH2 impairs DNA repair in breast 
epithelial cells. Neoplasia 2005, 7:1011-1019.
11.  McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, Giavara S, 
O’Connor MJ, Tutt AN, Zdzienicka MZ, Smith GC, Ashworth A: Defi  ciency in 
the repair of DNA damage by homologous recombination and sensitivity 
to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006, 66:8109-8115.
12.  Negrini S, Gorgoulis VG, Halazonetis TD: Genomic instability - an evolving 
hallmark of cancer. Nat Rev Mol Cell Biol, 11:220-228.
13. Esteller  M:  Epigenetic lesions causing genetic lesions in human cancer: 
promoter hypermethylation of DNA repair genes. Eur J Cancer 2000, 
36:2294-2300.
14.  Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, Bussaglia 
E, Prat J, Harkes IC, Repasky EA, Gabrielson E, Schutte M, Baylin SB, Herman JG: 
Promoter hypermethylation and BRCA1 inactivation in sporadic breast 
and ovarian tumors. J Natl Cancer Inst 2000, 92:564-569.
15.  Birgisdottir V, Stefansson OA, Bodvarsdottir SK, Hilmarsdottir H, Jonasson JG, 
Eyfj  ord JE: Epigenetic silencing and deletion of the BRCA1 gene in 
sporadic breast cancer. Breast Cancer Res 2006, 8:R38.
16.  Murphy CG, Moynahan ME: BRCA gene structure and function in tumor 
suppression: a repair-centric perspective. Cancer J, 16:39-47.
17.  Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-Labat ML, Gyorki DE, 
Ward T, Partanen A, Feleppa F, Huschtscha LI, Thorne HJ; kConFab, Fox SB, Yan 
M, French JD, Brown MA, Smyth GK, Visvader JE, Lindeman GJ: Aberrant 
luminal progenitors as the candidate target population for basal tumor 
development in BRCA1 mutation carriers. Nat Med 2009, 15:907-913.
doi:10.1186/bcr2871
Cite this article as: Stefansson OA, Esteller M: EZH2-mediated epigenetic 
repression of DNA repair in promoting breast tumor initiating cells. Breast 
Cancer Research 2011, 13:309.
Stefansson and Esteller Breast Cancer Research 2011, 13:309
http://breast-cancer-research.com/content/13/3/309
Page 2 of 2